If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Antineoplastic, mitogen-activated protein kinase 1 and 2 inhibitor
BRAF-positive (V600E or V600K)d metastatic melanoma† (in combination with encorafenib)
Chapter 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules > Other MEK Inhibitors
eChapter 2018: The Goodman & Gilman Year in Review New and Noteworthy FDA Approvals